Adrenal Tumor, Adrenocortical Carcinoma
Conditions
Keywords
adrenocortical carcinoma (ACC), adrenal tumor, metastastic adrenocortical carcinoma
Brief summary
The improvement of conventional imaging techniques has led to an increased detection rate of different adrenal tumors. Since those tumors can belong to a variety of entities the therapeutic consequences also show considerable variation. In order to definitely determine the type of tumor, invasive procedures like CT guided biopsies are often required, which could be avoided by a tumor specific imaging method. The presently available scintigraphic procedures are either time consuming and lead to high radiation exposure or are technically demanding. The steroidogenic enzymes CYP11B1 (11ß-hydroxylase)and CYP11B2 (aldosterone synthase)are expressed exclusively in the adrenal cortex and therefore represent suitable targets for a specific imaging technique. In our project we evaluate 123I-Iodometomidate which binds to both CYP11B enzymes as radiotracer for adrenal scintigraphy.
Interventions
DRUG123I-Iodometomidate
Sponsors
University of Wuerzburg
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adrenal tumor seen by CT or MRT-scan with diameter of at least 2 cm or patient with adrenocortical carcinoma and suspected metastasis or local recurrence or patients with primary hyperaldosteronismus and adrenal tumour \> 1 cm 2. Hormonal work up of of the adrenal tumor according to ENS@T (European network for the study of adrenal tumours)-criteria 3. Age ≥ 30 Jahre 4. Effective contraception (pearl index \<1%) 5. Written informed consent
Exclusion criteria
1. Pregnancy or breast feeding 2. Renal insufficiency (serum creatinine \> 2,0 mg/dl or MDRD \< 60 ml/min) 3. Known allergy to etomidate or constituents of the test drug
Countries
Germany
Outcome results
None listed